Two cardiovascular safety trials, the EMPA-REG OUTCOME trial (empagliflozin) and CANVAS (canagliflozin), did not report any significant difference in AF incidence for T2D patients on SGLT2 inhibitors compared with placebo (Zinman et al., 2015; Neal et al., 2017). Here, SLC5A2 is linked to type 2 diabetes mellitus.